COA establishes practice referral service for patients seeking cancer treatment during COVID-19 pandemic

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Hospitals have scaled back or closed cancer and blood disease services to make space for patients with COVID-19.

Recognizing that cancer care must continue, the Community Oncology Alliance has launched a referral service for patients seeking care in their communities.

Through the COA Patient-Practice Connector website, patients seeking care can fill out a brief contact form without sharing any personal health information. The COA team will then use that information to try to identify a practice that is still serving patients in their community within 24 hours.

The COA Patient-Practice Connector minimizes the amount of exposure that cancer patients may face when trying to find treatment. The website makes it easier to maintain social distance and find the provider that is the best fit for the patient.

No patient data will be stored or shared, and users can choose their provider. All data submitted to COA will be deleted immediately once a request is closed.

Table of Contents

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login